Roundtable discussion. Cost justification of innovative drugs through assessment of total health care costs.
Rybak
M J
MJ
School of Medicine, Wayne State University, Detroit, MI.
Allen
R
R
Craven
P C
PC
Freeman
R
R
Nightingale
C H
CH
Normand
C
C
Rubinstein
E
E
Schaison
G S
GS
Whitelaw
G
G
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D005060:Europe; D005572:Formularies, Hospital as Topic; D017048:Health Care Costs; D005102:Health Expenditures; D006295:Health Resources / Q000458:organization & administration; D010344:Patient Advocacy; D013222:State Medicine; D014481:United States